Phase 2 Lymphoma Trial, Recruiting NCT06678659 Sponsor: Recursion Pharmaceuticals Inc. Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06678659
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been confirmed by biopsy or tissue testing to have certain types of solid tumour cancers or certain types of lymphoma (a cancer of the lymphatic system) that cannot be surgically removed, have spread locally, or have spread to other parts of the body.
  • People whose cancer has continued to grow, has come back, or who could not tolerate at least one standard cancer treatment for their type of cancer — or who have been considered not suitable for standard treatment.
  • People who are reasonably well and able to carry out daily activities, as measured by a standard health scoring system (a score of 0 or 1 on the ECOG scale, or a score of 70 or above on equivalent scales used for younger patients).
  • People who have measurable signs of disease that can be detected and tracked using CT or MRI scans, according to established measurement guidelines.

Who may not be able to join:

  • People who have previously been treated with a drug that works by breaking down a protein called RBM39.
  • People who have significant problems with their stomach or digestive system, including conditions that affect how the body absorbs substances through the gut.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Recursion Pharmaceuticals Inc.
Registry
ClinicalTrials.gov
Start date
21 November 2024
Est. completion
30 October 2028

Where this trial is recruiting

🇨🇦 Canada 🇺🇸 United States

Primary endpoints

Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs); Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event; Phase 2- Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov